KR20210086662A - Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 - Google Patents

Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 Download PDF

Info

Publication number
KR20210086662A
KR20210086662A KR1020217015632A KR20217015632A KR20210086662A KR 20210086662 A KR20210086662 A KR 20210086662A KR 1020217015632 A KR1020217015632 A KR 1020217015632A KR 20217015632 A KR20217015632 A KR 20217015632A KR 20210086662 A KR20210086662 A KR 20210086662A
Authority
KR
South Korea
Prior art keywords
msc
leu
aoah
ser
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217015632A
Other languages
English (en)
Korean (ko)
Inventor
마이클 칼라한
셜리 에이치.제이. 메이
얀 왕
마리아 플로리안
케이트린 로웨
치안-장 리
Original Assignee
오타와 하스피털 리서치 인스티튜트
유나이티드 쎄러퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오타와 하스피털 리서치 인스티튜트, 유나이티드 쎄러퓨틱스 코포레이션 filed Critical 오타와 하스피털 리서치 인스티튜트
Publication of KR20210086662A publication Critical patent/KR20210086662A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217015632A 2018-10-29 2019-10-29 Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 Ceased KR20210086662A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
US62/752,000 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
KR20210086662A true KR20210086662A (ko) 2021-07-08

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015632A Ceased KR20210086662A (ko) 2018-10-29 2019-10-29 Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도

Country Status (10)

Country Link
US (1) US20220010281A1 (cg-RX-API-DMAC7.html)
EP (1) EP3874029B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372982B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210086662A (cg-RX-API-DMAC7.html)
CN (1) CN113166729A (cg-RX-API-DMAC7.html)
AU (1) AU2019370629A1 (cg-RX-API-DMAC7.html)
ES (1) ES2962812T3 (cg-RX-API-DMAC7.html)
IL (1) IL282820A (cg-RX-API-DMAC7.html)
SG (1) SG11202103509RA (cg-RX-API-DMAC7.html)
WO (1) WO2020087160A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302060A (en) * 2020-10-16 2023-06-01 Ottawa Hospital Res Inst Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用
WO2026101889A2 (en) * 2024-11-06 2026-05-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Acyloxyacyl hydrolase and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
JP2011528566A (ja) * 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
JP2012529895A (ja) * 2009-06-19 2012-11-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2658490C2 (ru) * 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
CA2928852A1 (en) * 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR102213527B1 (ko) * 2014-06-30 2021-02-09 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
CA3172801A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN108430480B (zh) * 2015-09-15 2022-08-02 康干细胞生物科技有限公司 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物

Also Published As

Publication number Publication date
AU2019370629A1 (en) 2021-05-20
WO2020087160A1 (en) 2020-05-07
EP3874029A1 (en) 2021-09-08
ES2962812T3 (es) 2024-03-21
EP3874029B1 (en) 2023-08-30
CN113166729A (zh) 2021-07-23
US20220010281A1 (en) 2022-01-13
IL282820A (en) 2021-06-30
EP3874029A4 (en) 2022-08-03
JP2022513379A (ja) 2022-02-07
JP7372982B2 (ja) 2023-11-01
CA3116196A1 (en) 2020-05-07
SG11202103509RA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
KR101992807B1 (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
JP2023052475A (ja) リソソーム障害を治療する方法
JP2020536510A (ja) 細胞の遺伝子修飾のための非組込みdnaベクター
CN1295617A (zh) 血管生成因子-血管内皮细胞生长因子vegf的突变体
US20220323503A1 (en) Methods and compositions for reconstituting microglia
JP7372982B2 (ja) Aoahを過剰発現する遺伝子組換え間葉系幹細胞及びその使用
CA3100262A1 (en) Compositions and methods for haematopoietic stem cell transplantation
US20080045699A1 (en) Interleukin-1 Related Gene and Protein
CN114452408A (zh) 靶向枯否细胞用于治疗癌症的药物组合物
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
CA3116196C (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211B (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211A (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
JP2023545539A (ja) ウイルス性疾患のための細胞ベースの治療
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
CN1307487A (zh) 治疗内毒素血症的方法
US20230302054A1 (en) Modification of t cells
JP2025530652A (ja) 遺伝子治療
JPWO2000008056A1 (ja) 新規なポリペプチド、そのポリペプチドをコードするcDNA、およびその用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000